Original Research
Original ResearchCitable benchmark research on U.S. healthcare RCM.
Original quarterly State of RCM benchmarks, annual denial-trend reports, industry surveys, and methodology papers from Medonix. Sourced from MGMA, HFMA, CMS, and AAPC published data combined with anonymized production data from our founding client cohort and independent surveys of U.S. revenue-cycle leaders. Free to download, citable with attribution.
Latest release
State of RCM, Q1 2026
A Medonix synthesis of MGMA and HFMA trailing 12-month benchmarks on clean-claim rate, days in A/R, denial mix, and payer behavior, with commentary from our founding client cohort. The full quarterly snapshot of where U.S. medical billing actually stands going into Q2 2026.
Inside the report
- First-pass clean-claim rate by specialty (top 35).
- Days in A/R by payer type and tier.
- Denial mix by CARC code, with quarter-over-quarter shift.
- Prior-auth turnaround time by payer.
- Patient-pay collection rate by statement cadence.
Free download · email opt-in for the PDF · no email sharing.
Sample
MGMA / HFMA published data + Medonix founding cohort
Anonymized production billing data across all active U.S. client practices, rolling measurement window ending the report date.
Want to cite this
Each report carries a citable byline, publication date, and methodology link. Methodology paper available at /resources/research/medonix-rcm-methodology-2026/.
How we research
Original data, sourced and disclosed.
Medonix research draws from three sources. First, published U.S. industry benchmarks from MGMA, HFMA, CMS, and AAPC. Second, anonymized production billing data from Medonix's founding client cohort, with prior contractual consent for benchmark inclusion. Third, independent surveys of U.S. healthcare practice owners, CFOs, and revenue-cycle leaders, with respondent identities anonymized. All sources are scoped, sampled, and reported with the methodology disclosed on every release.
PHI never appears in published research. All data is de-identified using HIPAA Safe Harbor with expert determination where required, audited under our SOC 2 Type II and HITRUST CSF scope. Cell-suppression rules prevent re-identification of small sample groups. The full data-handling protocol is in the methodology paper.
Citation with attribution is welcome. Every report carries a citable byline, publication date, sample size, and a link to the methodology. Journalists and analysts who want embargoed access to forthcoming reports or supplementary data should email the editorial team.
All published reports
6 reports across five formats.
- Annual report48 pages
2025 Healthcare Denial Trends Report
A full-year analysis of denial patterns synthesizing MGMA, HFMA, and CMS public data with anonymized claim records from Medonix's founding cohort. Year-over-year shifts in CO-16, CO-50, CO-97, and CO-197 reasons. The denial categories that grew, the ones that shrank, and the payer-specific drivers behind both.
MGMA / HFMA / CMS published data + Medonix cohortDownloadFebruary 15, 2026
- Industry survey36 pages
AI in Healthcare RCM: 2026 Adoption Survey
Independent survey of 412 U.S. healthcare practice owners, CFOs, and revenue-cycle leaders on AI adoption in billing operations: which workflows are automated, where human-in-the-loop is required, and the ROI being measured.
n = 412 practice leadersDownloadMarch 10, 2026
- Quarterly benchmark52 pages
Clean-Claim Rate Benchmarks Across 35 Specialties
The healthy range, the long tail, and the specialty-by-specialty story behind first-pass clean-claim rates. Cardiology, orthopedics, oncology, behavioral health, and 31 other specialties measured against the same methodology.
MGMA specialty benchmarks + Medonix cohort across 35 specialtiesDownloadApril 15, 2026
- White paper41 pages
No Surprises Act: Two-Year Impact Study (2024–2026)
A two-year retrospective on how the No Surprises Act has changed billing operations, IDR arbitration outcomes, and patient billing communications across emergency medicine, anesthesiology, radiology, and pathology.
~2.1M IDR-eligible claimsDownloadJanuary 22, 2026
- Methodology paper22 pages
Medonix RCM Methodology Paper, 2026 Edition
How Medonix measures every metric that appears in our research and case studies: data sources, measurement windows, anonymization protocol, and the specific calculation method behind every published benchmark.
Methodology referenceDownloadJanuary 10, 2026
Press, analyst, and academic access
Embargoed access, supplementary data, and interview requests.
Journalists at U.S. healthcare and trade publications, industry analysts, and academic researchers can request embargoed access to forthcoming reports, supplementary tables, and interviews with the Medonix research team.
Frequently asked
About Medonix research.
Methodology and access questions. For citation requests or partnership content, email hello@medonix.io.
Talk to RCM
Ready to recover every dollar your practice earns?
See your projected revenue lift in 60 seconds, or talk to a senior RCM strategist now. No commitment. Same-day slots available.
- 30-day parallel-run guarantee
- Targets written into the contract
- HIPAA · SOC 2 Type II · HITRUST